<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03487562</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP14012003</org_study_id>
    <nct_id>NCT03487562</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxicillin in Healthy Male Subjects</brief_title>
  <official_title>A Randomized, Open-label, Multiple Dose, Two-part Phase I Clinical Trial to Compare the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of DWP14012 After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxicillin in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, multiple dose, two-part phase I clinical trial to compare
      the pharmacokinetics, pharmacodynamics and safety/tolerability of DWP14012 after
      administrations of DWP14012 alone and combinations of DWP14012, Clarithromycin and
      Amoxicillin in healthy male subjects
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 10, 2018</start_date>
  <completion_date type="Anticipated">August 29, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 29, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax,ss: Maximum concentration of DWP14012, clarithromycin and metabolite and amoxicillin at steady state</measure>
    <time_frame>Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Part I: each period (Group A, B, C, D) Part II: Group A, B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin,ss: Minimum concentration of DWP14012, clarithromycin and metabolite and amoxicillin at steady state</measure>
    <time_frame>Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Part I: each period (Group A, B, C, D) Part II: Group A, B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cav,ss: Average concentration of DWP14012, clarithromycin and metabolite and amoxicillin at steady state</measure>
    <time_frame>Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Part I: each period (Group A, B, C, D) Part II: Group A, B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt,ss: Area under the drug concentration-time curve within a dosing interval at steady states</measure>
    <time_frame>Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Part I: each period (Group A, B, C, D) Part II: Group A, B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax,ss: Time of maximum concentration at steady state</measure>
    <time_frame>Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Part I: each period (Group A, B, C, D) Part II: Group A, B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2: Elimination half-life</measure>
    <time_frame>Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Part I: each period (Group A, B, C, D) Part II: Group A, B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of total time that the intragastric pH was above 4</measure>
    <time_frame>Period 1 Day -1 and Group A, C Day 7 0~24 hours</time_frame>
    <description>Part I</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of total time that the intragastric pH was above 4</measure>
    <time_frame>Day -1, Day 1, Day 7 0~24 hours</time_frame>
    <description>Part II</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of total time that the intragastric pH was above 6</measure>
    <time_frame>Period 1 day -1 and Group A, C Day 7 0~24 hours</time_frame>
    <description>Part I</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of total time that the intragastric pH was above 6</measure>
    <time_frame>Day -1, Day 1, Day 7 0~24 hours</time_frame>
    <description>Part II</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum gastrin concentration profile</measure>
    <time_frame>Period 1 Day -1 and Group A, C Day 7 pre-dose, 2, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Part I</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum gastrin concentration profile</measure>
    <time_frame>Day -1 pre-dose, 2, 4, 6, 8, 12 hours, Day 1 and 7 pre-dose, 2, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Part II</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse Events (AE)</measure>
    <time_frame>Day -2 (Randomization) to Day 60 (Post-study visit of Part I) and Day 42 (Follow up visit of Part II)</time_frame>
    <description>All AE standardized using MedDRA was assessed by investigator using the protocol defined grading system. Intensity was categorized as mild, moderate and severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Vital Sign findings</measure>
    <time_frame>Day -2 (Randomization) to Day 60 (Post-study visit of Part I) and Day 42 (Follow up visit of Part II)</time_frame>
    <description>Blood pressure(mmHg), pulse (beats/min) and body temperature(â„ƒ) were tested. The Average, Median, Standard Deviation, Min, Max values will be calculated to assess the safety/tolerability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Electrocardiogram(12-lead ECG) findings</measure>
    <time_frame>Day -2 (Randomization) to Day 54~60 (Post-study visit of Part I) and Day 36~42 (Follow up visit of Part II)</time_frame>
    <description>Ventricular rate(beats/min), RR, PR interval(msec), QRS duration(msec), QTcB and QTcF were recorded. The results of 12-lead ECG will be categorized Normal/Abnormal NCS(No clinically significant)/Abnormal CS(clinically significant).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Laboratory results</measure>
    <time_frame>Day -2 (Randomization) to Day 60 (Post-study visit of Part I) and Day 42 (Follow up visit of Part II)</time_frame>
    <description>Hematology, Blood chemistry, Coagulation and Urinalysis were tested. The Average, Median, Standard Deviation, Min, Max values will be calculated to assess the safety/tolerability.</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I: A-B-D-C A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I: B-C-A-D A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I: C-D-B-A A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I: D-A-C-B A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part II: (DWP14012 B mg + Clarithromycin 500 mg + Amoxicillin 1g) bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part II: (DWP14012 A mg + Clarithromycin 500 mg + Amoxicillin 1g) bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part II: (Lansoprazole 30 mg + Clarithromycin 500 mg + Amoxicillin 1g) bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 Amg</intervention_name>
    <description>DWP14012 Amg</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 Bmg</intervention_name>
    <description>DWP14012 Bmg</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Clarithromycin 500 mg</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Amoxicillin 1 g</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>Lansoprazole 30 mg</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males aged between 19 and 50 at screening

          -  Those whose weight is between 55 and 90 kg and BMI is between 18.0 and 27.0

          -  Part I: Those who have been helicobacter pylori negative at screening Part II: Those
             who have been helicobacter pylori positive at screening

          -  Those who are adequate to be subjects in this study upon judgment of the investigator
             after physical examination, clinical laboratory test, examination by interview, etc

        Exclusion Criteria:

          -  Those who have clinical significant liver, kidney, nervous system, respiratory,
             endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or
             past history

          -  Those who have gastrointestinal diseases or past history of gastrointestinal diseases
             (gastrointestinal ulcer, gastritis, gastrospasm, gastroesophageal reflux, Crohn's
             disease etc.) that may affect safety and pharmacokinetic/pharmacodynamic evaluation of
             study drug, and those who have past history of gastrointestinal surgery (however,
             except simple appendectomy and herniotomy)

          -  Those whose plasma AST (SGOT) and ALT (SGPT) exceed to the upper limit of the normal
             range

          -  Those who have anatomical disability in insertion and maintenance of pH meter catheter
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>In-Jin Jang, MD, PhD</last_name>
      <email>ijjang@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>In-Jin Jang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2018</study_first_submitted>
  <study_first_submitted_qc>April 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2018</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

